The Adenosine A2A Receptor as an Attractive Target for Parkinson's Disease Treatment

Drug News and Perspectives

Volumn 16, Issue 9, 2003, Pages 597-604

  Chen, Jiang Fan ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ALPHA TOCOPHEROL; APOMORPHINE; CAFFEINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; ISTRADEFYLLINE; LEVODOPA; NEUROTROPHIC FACTOR; QUINPIROLE; REMACEMIDE; SELEGILINE; THEOPHYLLINE;

CLINICAL TRIAL; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; DYSKINESIA; GENETICS; HUMAN; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN TARGETING; REVIEW; SYMPTOM;

ADENOSINE; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CAFFEINE; DOPAMINE; HUMANS; LEVODOPA; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RECEPTOR, ADENOSINE A2A; TREATMENT FAILURE;

EID: 0347719298     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2003.16.9.829342     Document Type: Review

References (81)

1. Agid, Y., Cervera, P., Hirsch, E. et al. Biochemistry, of Parkinson's disease 28 years later: A critical review. Mov Disord 1989, 4: S126-44.
2. Lang, A.E. and Lozano, A.M. Parkinson's disease. First of two parts. N Engl J Med 1998, 339: 1044-53.
3. Lang, A.E. and Lozano, A.M. Parkinson's disease. Second of two parts. N Engl J Med 1998, 339: 1130-43.
4. Obeso, J.A., Olanow, C.W. and Nutt, J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000, 23: S2-7.
5. Melamed, E., Offen, D., Shirvan, A., Djaldetti, R., Barzilai, A. and Ziv, I. Levodopa toxicity and apoptosis. Ann Neurol 1998, 44: S149-54.
6. Bezard, E., Brotchie, J.M. and Gross, C.E. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies. Nat Rev Neurosci 2001, 2: 577-88.
7. Fahn, S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000, 47: S2-9; discussion S9-11.
8. Jenner, P. Pathophysiology and biochemistry of dyskinesia: Clues for the development of non-dopaminergic treatment. J Neurol 2000, 247(Suppl 2): 1143-50.
9. Group, T.P.S. Effect of deprenyl on the progression of disability, in early Parkinson's disease. N Engl J Med 1989, 321: 1364-71.
10. Group, T.P.S. Effects of tocopherol and deprenyl on the progression of disability, in early Parkinson's disease. N Engl J Med 1993, 328: 176-83.
11. Shoulson, I. DATATOP: A decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism. Ann Neurol 1998, 44: S160-6.
12. Greenamyre, J.T., Eller, R.V., Zhang, Z., Ovadia, A., Kurlan, R. and Gash, D.M. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 1994, 35: 655-61.
13. Choi-Lundberg, D.L., Lin, Q., Chang, Y.N. et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997, 275: 838-41.
14. Gill, S.S., Patel, N.K., Hotton, G.R. et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003, 9: 589-95.
15. Olanow, C.W., Jenner, P. and Brooks, D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 1998, 44: S167-74.
16. Schapira, A.H. and Olanow, C.W. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann Neurol 2003, 53(Suppl 3): S149-57; discussion S157-9.
17. Chase, T.N., Konitsiotis, S. and Oh, J.D. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. Adv Neurol 2001, 86: 355-60.
18. Chase, T.N. and Oh, J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 2000, 23: S86-91.
19. Chen, J.-F. and Schwarzschild, M.A. Gene knockout approach to adenosine A2A receptors in Parkinson's disease. Drug Dev Res 2003, 59: 1-14.
20. Schwarzschild, M.A., Chen, J.F. and Ascherio, A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology 2002, 58: 1154-60.
21. Ferre, S., Fredholm, B.B., Morelli, M., Popoli, P. and Fuxe, K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997, 20: 482-7.
22. Richardson, P.J., Gubitz, A.K., Freeman, T.C. and Dixon, A.K. Adenosine receptor antagonists and Parkinson's disease: Actions of the A2A receptor in the striatum. Adv Neurol 1999, 80: 111-9.
23. Ongini, E. and Fredholm. B.B. Pharmacology of adenosine A2A receptors. Trends Pharmacol Sci 1996, 17: 364-72.
24. Kanda, T., Jackson, M.J., Smith, L.A. et al Adenosine A2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998, 43: 507-13.
25. Sauer, R., Maurinsh, J., Reith, U., Fulle, F., Klotz, K.N. and Muller, C.E. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. J Med Chem 2000, 43: 440-8.
26. Chen, J.F., Huang, Z., Ma, J. et al. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999, 19: 9192-200.
27. Ledent, C., Vaugeois, J.M., Schiffmann, S.N. et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 1997, 388: 674-8.
28. Fink, J.S., Weaver, D.R., Rivkees, S.A. et al. Molecular cloning of the rat A2 adenosine receptor: Selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 1992, 14: 186-95.
29. Schiffmann, S.N., Jacobs, O. and Vanderhaeghen, J.J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: An in situ hybridization histochemistry study. J Neurochem 1991, 57: 1062-7.
30. Schiffmann, S.N. and Vanderhaeghen, J.J. Adenosine A2 receptors regulate the gene expression of striatopallidad and striatonigral neurons. J Neurosci 1993, 13: 1080-7.
31. Martinez-Mir, M.I., Probst, A. and Palacios, J.M. Adenoxine A2 receptors: Selective localization in the human basal ganglia and alterations with disease. Neuroscience 1991, 42: 697-706.
32. Ferre, S., von Euler, G., Johansson, B., Fredholm, B.B. and Fuxe, K. Stimulation of high-affinity, adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 1991, 88: 7238-41.
33. Fuxe, K., Ferre, S., Zoli, M. and Agnati, L.F. Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res Brain Res Rev 1998, 26: 258-73.
34. Dunwiddie, T.V. and Masino, S.A. The tole and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001, 24: 31-55.
35. Mori, A., Shindou, T., Ichimura, M., Nonaka, H. and Kase, H. The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J Neurosci 1996, 16: 605-11.
36. Sebastiao, A.M. and Ribeiro, J.A. Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog Neurobiol 1996, 48: 167-89.
37. Pollack, A.E. and Fink, J.S. Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway. Neuroscience 1995, 68: 721-8.
38. Svenningsson, P., Le Moine, C., Fisone, G. and Fredholm, B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 1999, 59: 355-96.
39. Svenningsson, P., Lindskog, M., Ledent, C. et al. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc Natl Acad Sci USA 2000, 97: 1856-60.
40. Svenningsson, P., Lindskog, M., Rognoni, F., Fredholm, B.B., Greengard, P. and Fisone, G. Activation of adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience 1998, 84: 223-8.
41. Lindskog, M., Svenningsson, P., Fredholm, B.B., Greengard, P. and Fisone, G. Activation of dopamine D2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms. Neuroscience 1999, 88: 1005-8.
42. Ferre, S., Fuxe. K., von Euler, G., Johansson, B. and Fredholm, B.B. Adenosine-dopamine interactions in the brain. Neuroscience 1992, 51: 501-12.
43. Fredholm, B.B., Battig, K., Holmen, J., Nehlig, A. and Zvartau, E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999, 51: 83-133.
44. Barraco, R.A., Martens, K.A., Parizon, M. and Normile, H.J. Adenosine A2a receptors in the nucleus accumbens mediate locomotor depression. Brain Res Bull 1993, 31: 397-404.
45. Barraco, R.A.. Martens, K.A., Parizon, M. and Normile, H.J. Role of adenosine A2a receptors in the nucleus accumbens. Prog Neuropsychopharmacol Biol Psychiatry 1994, 18: 545-53.
46. Rimondini, R., Ferre, S., Gimenez-Llort, L., Ogren, S.O. and Fuxe, K. Differential effects of selective adenosine A1 and A2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. Eur J Pharmacol 1998, 347: 153-8.
47. Grondin, R., Bedard, P.J., Hadj Tahar, A., Gregoire, L., Mori, A. and Kase, H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 1999, 52: 1673-7.
48. Morelli, M. and Pinna, A. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Neuro Sci 2001, 22: 71-2.
49. Pinna, A., di Chiara, G., Wardas, J. and Morelli, M. Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats. Eur J Neurosci 1996, 8: 1176-81.
50. Aoyama, S., Kase, H. and Borrelli, E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci 2000, 20: 5848-52.
51. Chen, J.F., Moratalla, R., Impagnatiello, F. et al. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci USA 2001, 98: 1970-5.
52. Shindou, T., Mori, A., Kase, H. and Ichimura, M. Adenosine A(2A) receptor enhances GABA(A)-mediated IPSCs in the rat globus pallidus. J Physiol 2001, 532: 423-34.
53. Kanda, T., Jackson, M.J., Smith, L.A. et al. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 of D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000, 162: 321-7.
54. Kanda, T., Tashiro, T., Kuwana, Y. and Jenner, P. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport 1998, 9: 2857-60.
55. Pinna, A., Fenu, S. and Morelli, M. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 2001, 39: 233-8.
56. Shiozaki, S., Ichikawa, S., Nakamura, J., Kitamura, S., Yamada, K. and Kuwana, Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 1999, 147: 90-5.
57. Richardson, P.J., Kase, H. and Jenner, P.G. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 1997, 18: 338-44.
58. Shindou, T., Nonaka, H., Richardson, P.J., Mori, A., Kase, H. and Ichimura, M. Presynaptic adenosine A(2A) receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus. Br J Pharmacol 2002, 136: 296-302.
59. Halldner, L., Lozza, G., Lindstrom, K. and Fredholm, B.B. Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist. Eur J Pharmacol 2000, 406: 345-54.
60. Hubble, J.P., Hauser, R. and Kyowa, C. A novel adenosine antagonist (KW6002) as a treatment for advanced Parkinson Disease with motor complications. Ann Meet Am Assoc Neurol 2002.
61. Sherzai, A., Bara-Jimenez, W., Gillespie, M. et al. Adenosine A2a antagonist treatment of Parkinson's disease. Ann Meeting Am Assoc Neurol 2002.
62. Fredduzzi, S., Moratalla, R., Monopoli, A. et al. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci 2002, 22: 1054-62.
63. Lundblad, M., Vaudano, E. and Cenci, M.A. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of L-dopa-induced dyskinesia. J Neurochem 2003, 84: 1398-410.
64. Bove, J., Marin, C., Bonastre, M. and Tolosa, E. Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemi-parkinsonian rats. Synapse 2002, 46: 251-7.
65. Bibbiani, F., Oh, J.D., Petzer, J.P. et al. A2A receptor antagonist prevents the development of dopamine agonist-induced motor complications in primate and rodent models of Parkinson's disease. Ann Meet Soc Neurosci, Orlando, Florida, 2002.
66. Monopoli, A., Lozza, G., Forlani, A., Mattavelli, A. and Ongini, E. Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 1998, 9: 3955-9.
67. Pillis, J.W. The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res 1995, 705: 79-84.
68. Jones, P.A., Smith, R.A. and Stone, T.W. Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A2A receptor antagonist. Brain Res 1998, 800: 328-35.
69. Jones, P.A., Smith, R.A. and Stone, TW. Protection against kainate-induced excitotoxicity, by adenosine A2A receptor agonists and antagonists. Neuroscience 1998, 85: 229-37.
70. Popoli, P., Pintor, A., Domenici, M.R. et al. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: Possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci 2002, 22: 1967-75.
71. Dall'Igna, O.P., Porciuncula, L.O., Souza, D.O., Cunha, R.A. and Lara, D.R. Neuroprotection by caffeine and adenosine A(2A) receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 2003, 138: 1207-9.
72. Chen, J.F., Xu, K., Petzer, J.P. et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001, 21: RC143.
73. Ikeda, K., Kurokawa, M., Aoyama, S. and Kuwana, Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 2002, 80: 262-70.
74. Dixon, A.K., Gubitz, A.K., Sirinathsinghji, D.J., Richardson, P.J. and Freeman, T.C. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 1996, 118: 1461-8.
75. Rosin, D.L., Robeva, A., Woodard, R.L., Guyenet, P.G. and Linden, J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol 1998, 401: 163-86.
76. Ross, G.W., Abbott, R.D., Petrovitch, H. et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000, 283: 2674-9.
77. Ascherio, A., Zhang, S.M., Hernan, M.A. et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001, 50: 56-63.
78. Ascherio, A., Chen, H., Schwarzschild, M.A., Zhang, S.M., Colditz, G.A. and Speizer, F.E. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 2003, 60: 790-5.
79. Oztas, E., Xu, K., Kalda, A., Irrizary, M., Schwarzschild, M.A. and Chen, J.F. Caffeine attenuates MPTP-induced loss of dopaminergic neurons in substantia nigra in mice. Ann Meet Soc Neurosci, Orlando, Florida, 2002.
80. Gevaerd, M.S., Takahashi, R.N., Silveira, R. and Da Cunha, C. Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats. Brain Res Bull 2001, 55: 101-6.
81. Xu, K., Xu, Y.H., Chen, J.F. and Schwarzschild, M.A. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity, shows no tolerance to chronic caffeine administration in mice. Neurosci Lett 2002, 322: 13-6.